Business Context and Reporting Period
Company: PAVmed Inc. (PAVM)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: PAVmed is a multi-product life sciences company operating through distinct subsidiaries. Key assets include Lucid Diagnostics (EsoGuard test) and Veris Health (Veris Cancer Care Platform). The company utilizes an incubator model to advance other technologies.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Sept 30, 2024 Balance Sheet |
|---|---|---|---|
| Revenue | $0.996 million | $2.985 million | - |
| Operating Loss | $(11.578) million | $(39.300) million | - |
| Net Income (Loss) Attributable to PAVmed | $64.399 million | $38.360 million | - |
| Net Income (Loss) Per Share (Basic) | $6.43 | $3.30 | - |
| Cash and Cash Equivalents | - | - | $0.765 million |
| Total Assets | - | - | $30.550 million |
| Total Liabilities | - | - | $39.937 million |
| Senior Secured Convertible Notes (Fair Value) | - | - | $32.050 million |
| Working Capital | - | - | $(35.427) million |
Material Changes vs. Prior Period
- Deconsolidation of Lucid Diagnostics: On September 10, 2024, PAVmed lost controlling interest in Lucid Diagnostics due to preferred equity transactions and termination of voting proxies. Lucid is now accounted for as an equity method investment. This resulted in a non-cash gain on deconsolidation of $72.287 million, which drove the reported net income for the quarter and year-to-date.
- Revenue Growth: Revenue increased to $0.996 million (Q3 2024) from $0.791 million (Q3 2023) and $2.985 million (9M 2024) from $1.403 million (9M 2023), primarily due to increased volume of EsoGuard tests.
- Expense Reduction: Operating expenses decreased significantly compared to the prior year due to the deconsolidation of Lucid. Sales and marketing expenses dropped $1.1 million (Q3) and $1.4 million (9M); R&D expenses dropped $1.7 million (Q3) and $5.6 million (9M).
- Debt Fair Value: The fair value of Senior Secured Convertible Notes decreased from $44.2 million (Dec 31, 2023) to $32.05 million (Sept 30, 2024), largely due to the removal of Lucid's debt upon deconsolidation and principal repayments via stock conversion.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for 12 months following the report date. This is due to negative working capital of approximately $35.4 million, low cash balances ($0.765 million), and reliance on future financing or revenue growth.
- Nasdaq Compliance: The company received a notice of non-compliance with Nasdaq listing standards (market value of listed securities below $35 million). A hearing panel granted an extension until January 31, 2025, to regain compliance.
- Debt Covenants: The company was not in compliance with financial covenants (Market Cap Test and Debt to Market Cap Ratio) between September 1 and November 11, 2024. The investor agreed to waive non-compliance through December 31, 2024.
- Unusual Items:
- Gain on Deconsolidation: $72.3 million non-operating gain.
- Debt Extinguishment Losses: Approximately $1.4 million (Q3) and $2.5 million (9M) recognized due to debt conversions and acceleration floor payments.
- Deemed Dividend: A $7.5 million deemed dividend was charged to accumulated deficit in March 2024 related to the exchange of Lucid preferred stock.
- Outlook: Future operations depend on controlling costs, increasing revenue from the Veris platform, and raising additional capital through equity or debt financings.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $0.765 million cash balance against the $35.4 million negative working capital and upcoming debt obligations.
- Debt Maturity: Confirm the status of the Senior Secured Convertible Notes (maturing April and September 2025) and the terms of the recent covenant waivers.
- Nasdaq Status: Monitor the company's progress toward regaining compliance with Nasdaq listing standards by the January 31, 2025 deadline.
- Lucid Investment: Assess the fair value of the remaining equity method investment in Lucid Diagnostics ($25.5 million) and the impact of Lucid's independent financing activities on PAVmed's future returns.
- Revenue Sustainability: Evaluate the sustainability of EsoGuard revenue growth given the deconsolidation of Lucid's operating expenses and the reliance on third-party reimbursement coverage.